蓝帆医疗(002382) - 2026年3月12日投资者关系活动记录表

Group 1: Company Strategy and Development - The year 2026 marks the beginning of the company's "15th Five-Year" development strategy, following a transformative "13th Five-Year" and a restructuring "14th Five-Year" period [2][3] - Key drivers for the glove business in 2026 include: industry entering a health cycle, rising industry concentration, price increases due to supply chain dynamics, and enhanced innovation capabilities [3][4] Group 2: Business Segments Performance - The company has three main business segments: Health Protection, Cardiovascular, and Emergency Rescue, with Health Protection being the highest revenue contributor [3][5] - The Cardiovascular segment has seen a recovery with a gross margin returning to approximately 65% post-national procurement [3][4] - The Emergency Rescue segment is currently smaller in scale and is undergoing a sale process to focus on the core businesses [5] Group 3: Financial Performance and Challenges - The company reported losses in 2025 primarily due to the Health Protection segment, affected by international trade policies and one-time tax impacts [3][4] - The Health Protection segment has a production capacity of around 1 billion nitrile and PVC gloves, with full production achieved in Shandong [4][5] - Rising raw material prices due to geopolitical factors have led to an industry-wide price increase, with historical trends indicating that glove prices typically rise faster than raw material costs [4][6] Group 4: Raw Material Supply and Procurement Strategy - The company has unique advantages in raw material procurement, including a partnership with a Thai investor providing stable nitrile latex supply and a domestic supplier for PVC gloves [6][7] - A multi-channel procurement strategy is in place to mitigate risks associated with raw material sourcing [6][7] Group 5: Internationalization and Market Expansion - The Cardiovascular segment has a strong international presence, with overseas revenue accounting for approximately 60% of its total [12][13] - New products such as the TAVR system and IVL therapy system have received EU certifications and are expected to drive future growth in international markets [12][13] Group 6: Future Outlook and Investment Plans - The company is focusing on optimizing existing capacities and enhancing profitability before considering overseas factory expansions [11][12] - Plans for convertible bonds are underway, with strategies to improve financial strength and facilitate conversion through operational and financing measures [13]